Skip to main content

Fitzgerald Kevin Joseph's Form 4 filing

Alnylam Pharmaceuticals, Inc.ALNY · filed Nov 19, 2025

Accession no.
0001735276-25-000123
Filed
Nov 19, 2025
Trade date
Nov 17, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 12 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.48M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fitzgerald Kevin JosephCIK 0001886431Officer (CSO & EVP, Head of Research)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 17, 2025Common StockMOption exerciseAcquired+8,161$119.13+$972,219.9333,392Direct
Nov 17, 2025Common StockSSaleDisposed−8,168$449.00−$3,667,43225,224Direct
Nov 17, 2025Common StockSSaleDisposed−96$450.09−$43,208.6425,128Direct
Nov 17, 2025Common StockSSaleDisposed−129$451.51F2−$58,244.7924,999Direct
Nov 17, 2025Common StockSSaleDisposed−368$455.24F3−$167,528.3224,631Direct
Nov 17, 2025Common StockSSaleDisposed−364$456.25F4−$166,07524,267Direct
Nov 17, 2025Common StockSSaleDisposed−262$457.39F5−$119,836.1824,005Direct
Nov 17, 2025Common StockSSaleDisposed−794$458.41F6−$363,977.5423,211Direct
Nov 17, 2025Common StockSSaleDisposed−622$459.89F7−$286,051.5822,589Direct
Nov 17, 2025Common StockSSaleDisposed−707$460.84F8−$325,813.8821,882Direct
Nov 17, 2025Common StockSSaleDisposed−323$461.96F9−$149,213.0821,559Direct
Nov 17, 2025Common StockSSaleDisposed−295$463.08F10−$136,608.621,264Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 17, 2025Common StockMOption exerciseDisposed−8,161$0.00$0839Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.41 to $451.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F3

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.92 to $455.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F4

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.97 to $456.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F5

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $457.00 to $457.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F6

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $458.01 to $458.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F7

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $459.40 to $460.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F8

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $460.46 to $461.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F9

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $461.50 to $462.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F10

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $462.82 to $463.46. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)